Gubra A/S (GUBRF)

OTCMKTS · Delayed Price · Currency is USD
60.15
0.00 (0.00%)
Jun 2, 2026, 10:13 AM EDT
Market Cap850.42M -13.4%
Revenue (ttm)414.54M +892.2%
Net Income265.78M
EPS16.15
Shares Out n/a
PE Ratio3.20
Forward PE30.60
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Open60.15
Previous Close60.15
Day's Range60.15 - 60.15
52-Week Range60.15 - 102.41
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateAug 20, 2026

About Gubra

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinfor... [Read more]

Industry Commercial Physical and Biological Research
Founded 2008
Employees 300
Stock Exchange OTCMKTS
Ticker Symbol GUBRF

Financial Performance

Financial numbers in DKK Financial Statements

News

Gubra Earnings release: Q1 2026

Gubra released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.

22 days ago - Filings

Gubra Slides: Q1 2026

Gubra has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.

22 days ago - Filings

Gubra Earnings Call Transcript: Q1 2026

Q1 2026 saw strong biotech pipeline momentum, facility expansion, and key leadership hires. Revenue improved due to Amylyx milestone, while CRO showed sequential growth but faces ongoing market volatility. Two partnered assets advance to phase II in 2026.

4 weeks ago - Transcripts

Gubra Earnings release: Q1 2026

Gubra released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.

4 weeks ago - Filings

Gubra Slides: Q1 2026

Gubra has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.

4 weeks ago - Filings

Gubra Slides: Investor presentation

Gubra has posted slides in relation to its latest quarterly earnings report, which was published on April 15, 2026.

7 weeks ago - Filings

Gubra Slides: Investor presentation

Gubra has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.

2 months ago - Filings

Gubra Annual report: Q4 2025

Gubra has published its Q4 2025 annual report on March 3, 2026.

3 months ago - Filings

Gubra Slides: Q4 2025

Gubra has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 3, 2026.

3 months ago - Filings

Gubra Earnings Call Transcript: Q4 2025

Record 2025 results driven by the AbbVie deal, with revenue of DKK 2.6 billion and net profit of DKK 1.7 billion. CRO growth slowed due to US biotech headwinds but is expected to rebound in 2026. Pipeline expansion and new ventures are set to drive future growth.

3 months ago - Transcripts

Gubra Annual report: Q4 2025

Gubra has published its Q4 2025 annual report on February 27, 2026.

3 months ago - Filings

Gubra Slides: Q4 2025

Gubra has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 27, 2026.

3 months ago - Filings

Gubra Slides: Investor presentation

Gubra has posted slides in relation to its latest quarterly earnings report, which was published on December 18, 2025.

5 months ago - Filings

Gubra Earnings release: Q3 2025

Gubra released its Q3 2025 earnings on November 7, 2025, summarizing the period's financial results.

7 months ago - Filings

Gubra Slides: Q3 2025

Gubra has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 7, 2025.

7 months ago - Filings

Gubra Earnings Call Transcript: Q3 2025

Record revenue and margins were achieved, driven by milestone deals and strong Discovery & Partnerships performance, despite a 5% CRO revenue decline due to macroeconomic headwinds. UCM2 and ABBV-295 programs advanced, with clinical trials planned and a major out-licensing deal completed.

7 months ago - Transcripts

Gubra Earnings release: Q3 2025

Gubra released its Q3 2025 earnings on November 7, 2025, summarizing the period's financial results.

7 months ago - Filings

Gubra Slides: Q3 2025

Gubra has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 7, 2025.

7 months ago - Filings

Gubra Quarterly report: Q2 2025

Gubra has published its Q2 2025 quarterly earnings report on August 21, 2025.

10 months ago - Filings

Gubra Slides: Q2 2025

Gubra has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 21, 2025.

10 months ago - Filings

Gubra Earnings Call Transcript: Q2 2025

Record H1 2025 revenue driven by a major AbbVie deal boosted Discovery & Partnerships, while CRO services faced U.S. market headwinds and revised guidance. Strong clinical progress in obesity pipeline and a new focus on women's health were highlighted.

10 months ago - Transcripts

Gubra Quarterly report: Q2 2025

Gubra has published its Q2 2025 quarterly earnings report on August 21, 2025.

10 months ago - Filings

Gubra Slides: Q2 2025

Gubra has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 21, 2025.

10 months ago - Filings